Exact Sciences’ newly FDA-approved Cologuard Plus colorectal cancer test offers a significant upgrade, boasting improved sensitivity and specificity over its predecessor. With 95% sensitivity and 94% specificity, this non-invasive stool-based test could set a new standard in cancer screening, reducing false positives. Although Exact Sciences missed out on a Medicare price premium initially, analysts remain optimistic about future pricing increases. As Exact Sciences prepares for a 2025 launch, it aims to improve its margins and defend market share amidst rising competition from blood-based tests by rivals like Guardant Health. Could this test reshape cancer screening?
Exact Sciences wins FDA approval for Cologuard Plus colorectal cancer test (Medtech Dive)
0